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Abstract: The aim of this study was to selectively profile the activation status of mammalian target of
rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer speci-
mens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a novel type of
microfluidic gene array to examine the expression of 15 human tumor suppressors and oncogenes in ovari-
an cancer specimens of 53 patients, benign ovarian cysts of 29 women (endometrial and simple) and 11
healthy ovaries of individuals in whom the material was obtained during total hysterectomies performed
because of fibroid changes. The array was custom-designed to include the following genes: NF1, RHEB,
mTOR1, AKT-1, PTEN, TSC1, TSC2, KRAS, RPS6KB1, 4EBP1, TP53, EIF4E, STK11, PIK3CA and BECN1.
Confirmatory immunohistochemical detection was performed for a group of selected proteins. Particularly
significant differences were observed as to the expression of PTEN (p < 0.0001), TP53 (p = 0.0003), PIK3CA
(p = 0.0003) and BECN1 (p = 0.0014) which were shown to be downregulated in cancer patients when
compared to healthy ovaries and benign ovarian cysts (endometrial and simple). These markers did not
show association with grade or stage of the tumor. Immunohistochemistry showed that PTEN, TP53, PIK3CA
and BECN1 proteins are expressed in ovarian cancer. Our results indicate that there are significant differ-
ences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be
associated with the pathogenesis of ovarian cancer. (Folia Histochemica et Cytobiologica 2011; Vol. 49,
No. 2, pp. 317–324)
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Introduction
Ovarian cancer remains a highly lethal disease which
in developed countries accounts for more deaths than
all other gynecological malignancies combined: an
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estimated 22,430 new cases and 15,280 deaths oc-
curred in 2007 in the USA alone [1].
The molecular pathology of ovarian carcinomas
is heterogeneous and involves various putative pre-
cursor lesions and multiple pathways of development.
Although very little is known regarding the molecu-
lar mechanisms involved in the biochemical alter-
ations of cell signaling, most of them lead to abnor-
mal growth which depends on altered stimulation by
growth factor receptor-cell signaling pathways. Stim-
uli follow different pathways, but a substantial num-
ber of them converge in the mammalian target of ra-
pamycin (mTOR) which plays a central role in can-
cerogenesis and, as we have recently shown, its key
pathway components have been implicated in the
development of endometriosis [2, 3].
mTOR is a conserved seronine/threonine kinase
which functions by integrating extracellular signals
(growth factors and hormones). mTOR enhances
translation initiation in part by phosphorylating
a group of its major targets, such as: transcription fac-
tor eIF4E (mRNA cap-binding protein) which is
a known potent oncogene, and selected tumor suppres-
sor genes, like: 4E-BP1 (the so called inhibitory
4E-binding protein) considered a hallmark of cell signal-
ing in ovarian cancer [4], and ribosomal protein S6
kinases (e.g. oncogene S6K1) that co-operate to reg-
ulate gene expression and translation processes [2].
S6K1 has also been shown to repress the phos-
phatidylinositol 3-kinase (PI3K) related pathways.
PI3K oncogene is a heterodimer that is composed of
a p85 regulatory and a p110 catalytic subunit (coded
for by the PIK3CA), and its aberrantly high activity
has been implicated in cell transformation and tumor
progression in a variety of human cancers [5]. PI3K
converts PIP2 to PIP3 (phosphatidylinositol-3,
4,5-triphosphate), which is actively opposed by its phos-
phatase PTEN (phosphatase and tensin homolog de-
leted on chromosome ten) tumor suppressor of which
loss of function has been found in many advanced
human cancers [6]. PIP3 recruits one of the most po-
tent oncogenes AKT [5] to the membrane where it is
activated by phosphorylation. Once activated, AKT
phosphorylates a multitude of proteins, with the net
result of increased cellular survival, proliferation,
growth and metabolism. Specifically, phosphorylation
of mTOR by AKT occurs through inactivation of the
tuberous sclerosis complex — heterodimer consist-
ing of unphosphorylated tumor suppressors TSC1 and
TSC2 [7]. The complex acts as a GTPase-activating
protein (GAP), inhibiting the small G-protein Rheb
(Ras homolog enriched in brain), an oncogene of
which expression is elevated in many tumor cells [8].
TSC1, TSC2 and Rheb also contribute to the acti-
vation of mTOR after losing such tumor suppressors
as: NF1 (neurofibromatosis 1), LKB1 (also known as
serine–threonine kinase 11) or p53 [2]. NF1 also en-
codes a GAP for Rat Sarcoma (RAS), of which mu-
tations result in hyperactivation of the protein and
are among the most frequent alterations in human
cancers. It has also been found that prolonged acti-
vation of k-ras can occur in tumors by mechanisms
that do not involve mutations [9].
P53, which plays a pivotal role in safeguarding the
integrity of the genome, harbors mutations in more
than 50% of human cancers of all tissue origins [10]
and is also a central signal integrator of stress, such
as DNA damage or hypoxia. When activated, it ini-
tiates cellular tumor suppression programs such as
apoptosis, cell cycle arrest or autophagy.
Autophagy was recently established as a novel tu-
mor suppression mechanism which leads to lysosom-
al degradation of cytoplasmic components. Genetic
evidence shows that compromised autophagy plays
a causal role in tumorigenesis. Specifically, decreased
expression of BECN1 (beclin-1) is associated with
human breast cancer, ovarian and prostate cancer
[11]. Moreover, autophagy is negatively regulated by
mTOR which is a central protein that integrates sig-
nals from nutrients and growth factors [12].
Our aim was to profile the expression status of
the aforementioned key tumor suppressor genes and
oncogenes that could be functionally related to the
mTOR pathway [13] in ovarian cancer. We also at-
tempted to show that the low-density microfluidic
gene chip is an effective technique to examine the
expression of different genes in such a heterogeneous
tissue as the ovary.
Material and methods
Tissue samples (n = 93) from patients with invasive ovarian
cancer, benign ovarian cysts and normal ovaries were col-
lected during surgery performed in the Department of Gy-
necology of the Medical University of Bialystok, the De-
partment of Gynecologic Oncology of the Medical Univer-
sity of Gdansk, and the Department of Gynecology and
Gynecologic Oncology of the Military Institute of Health
Sciences in Warsaw. The operations were performed in 2006
and 2009. We initially collected samples from a total of 80
patients diagnosed with an ovarian malignancy (n = 53) on
frozen section who underwent full surgical staging or tu-
mor debulking as clinically indicated. A piece of each col-
lected tissue was divided into two halves and placed sepa-
rately in buffered formalin for histopathological studies and
RNA later (Sigma Aldrich, Poland) for molecular analysis.
The latter was stored for 24 hours at 4°C and then tissues
were transferred and stored at –80°C. Two opposite mar-
gins were checked by means of histology in all cases and
proven to consist of cancer tissue only (> 90%). Benign
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ovarian cysts (endometrial and simple), initially collected
during laparoscopy from 45 patients, as well as normal ova-
ries removed from 19 patients during total hysterectomy
performed because of fibroids during laparotomy, were cho-
sen as controls. The study was approved by the Institutional
Review Board (IRB) and the patients gave their informed
consent before inclusion in the study.
The RNA isolation was performed using a total RNA
isolation kit from Macherey-Nagel (Duren, Germany) accord-
ing to the manufacturer’s protocol. RNA concentration and
quality was determined using a NanoDrop spectrophotome-
ter (Kisker, Steinfurt, Germany) and the Agilent Bioanalyz-
er 2100 (Agilent Technologies, Perlan, Poland).
Total RNA was subsequently converted to single strand-
ed cDNA and loaded into the custom-designed 16 gene ex-
pression assay (three replicates per assay) of the TaqMan
real-time PCR microfluidic gene array system (Applied Bio-
systems, Warsaw, Poland). The assay Ids, including house-
-keeping gene, and detailed procedures (including thermal
cycle PCR conditions) were exactly the same as those de-
scribed in our most recent publication [3].
Gene expression values (RQ-relative quantity) were cal-
culated based on the DDCt method, where one sample was
designated as the calibrator, through which all other sam-
ples were analyzed [14].
Immunohistochemistry. For the immunohistochemical
studies, a representative section from the resected speci-
men was selected. Four-micrometer-thick sections were
deparaffinized and dehydratated. Endogenous peroxidase
activity was blocked by Peroxidase Blocking Reagent for five
minutes at room temperature. For antigenic recovery, the
material was immersed in citrate buffer (pH = 6) and placed
in a microwave oven for 20 minutes. After rinsing in PBS
buffer pH = 7.4 (P53, BECN1) and Tris (PTEN, PIK3CA),
the sections were incubated with studied primary antibod-
ies for 24 hours at 4°C, or ten minutes at room tempera-
ture. PTEN (anti-human/mouse PTEN), p53 (mouse mon-
oclonal antibody), PIK3CA (rabbit anti-PIK 3CA) and
BECN1 (mouse monoclonal antibody) were assessed using
monoclonal mouse antibodies, namely: anti-human PTEN
from R&D Systems (clone 217702) which was diluted 1:40
in Tris buffer pH = 7.4; p53 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, clone BP53.12) diluted 1:100 in block-
ing serum, PIK3CA (Sigma, HPA009985) diluted 1:50 in
Tris buffer pH7.4 and BECN1 (Santa Cruz Biotechnology,
clone BP53.12) diluted 1:100 in blocking serum.
Sections were then incubated with biotinylated second-
ary antibody at room temperature for 30 minutes. After-
wards, sections were incubated with ABC solution (Santa
Cruz Biotechnology, BECN, P53 and PIK3CA) and R&D
Systems Cell and Tissue Staining Kits (PTEN), at room tem-
perature for 30 minutes, followed by diaminobenzidine
tetrachloride solution at room temperature for ten minutes,
and counterstained in Mayer’s hematoxylin. Sections were
subsequently dehydrated, transferred to xylene and even-
tually mounted in a resinous mountant. The expression of
studied proteins was evaluated with the use of light micros-
copy (Olympus CX21). Appropriate immunohistochemical
controls, positive and negative, were carried out.
For statistical analysis, the Kruskal–Wallis nonparamet-
ric test was used to compare RQ values of three groups to-
gether (ovarian cancer vs. benign ovarian cysts vs. healthy
ovaries). Wilcoxon rank-sum test was then used for the com-
parison of RQ values between ovarian cancer vs. benign
ovarian cysts, ovarian cancer vs. healthy ovaries and benign
ovarian cysts vs. healthy ovaries. The significance level was
equal to 0.05. The statistical analysis was performed using
a SAS STAT package.
Results
Patient clinico-pathological characteristics are pre-
sented in Table 1. Detailed RQ and p values in three
main study groups are presented in Table 2. Because
our control group consisted of two relatively differ-
ent subgroups of tissues (normal ovaries and benign
cysts), we decided to divide our study group into three
groups and then perform statistical analysis on them.
We succeeded in obtaining adequate RNA only from
53 patients with ovarian cancer, 29 with benign ovari-
an cysts and 11 healthy ovaries. These comprised our
Table 1. Patient clinico-pathological characteristics
Characteristics Number %
Number of evaluated patients 93 100
Age (years)
Median 49
Range 21–86
Types of tissues
Normal ovaries 11 11.8
Benign ovarian cysts 29 31.1
Endometriomas 19 20.4
Simple 10 10.7
Malignant 53 56.9
Stage of disease
 I 8 15.09
II 5 9.4
III 31 58.4
IV 9 16.9
Histological type
Serous 34 64.1
Endometrioid 8 15
Clear cell 5 9.4
 Mucinous 4 7,5
Mixed 2 3,7
Grade
G1 10 18.8
G2 18 33.9
G3 25 47.1
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main study group and were used for further molecu-
lar analysis.
By the use of Kruskal–Wallis, we could compare
three groups together. We found significant differ-
ences for most of the studied genes, except for
mTOR (p = 0.86), KRAS (p = 0.59) and AKT1
(p = 0.16). Then we attempted to compare, by the use
of Wilcoxon rank-sum test, whether differences ex-
isted as to the RQ values between combinations of
subgroups, i.e. ovarian cancer vs. healthy ovaries,
ovarian cancer vs. benign cysts and healthy ovaries
vs. benign cysts. We found that only for four genes,
namely PTEN, TP53, PIK3CA and BECN1, were
there significant differences between ovarian can-
cer and each of the two control groups (Table 2).
The median RQ values of the four genes were sig-
nificantly lower in patients with ovarian cancer com-
pared to two control groups. No differences were
found between normal ovaries and benign cysts for
three of the four genes i.e. TP53 (p = 0.55), PIK3CA
(p = 0.98) and BECN1 (p = 0.65). The only excep-
tion, PTEN, exerted the highest median gene expres-
sion in normal ovaries which was significantly high-
er than in benign cysts (p = 0.003) and ovarian can-
cer subgroup (p = 0.0019), which showed the low-
est median concentration. Analysis carried out with
a group of malignant tumors (n = 53) showed no
statistically significant correlation between all 15
tested genes and age, grade (I, II vs. III) or clinical
stage (I, II vs. III, IV).
We also decided to study differences in the medi-
an RQ values of all genes between two histological
types i.e. serous and endometrial. The number of oth-
er types was too small for statistical analysis. We found
that the differences were significant for two out of 15
studied genes, namely BECN1 (p = 0.008) and TSC2
(p = 0.034). The expression of both genes was de-
creased in serous ovarian cancer: respective median
(minimum-maximum) RQ values for BECN1 and
TSC2 were: 0.36 (0.09–6.56) and 0.32 (0.08–15.5) com-
pared to endometrioid type: respectively 0.77 (0.4–
–9.8) and 0.73 (0.46–2.89).
Localization of PTEN, TP53, PIK3CA
and BECN1 in ovarian cancer
In order to confirm protein expression of genes that
were differentially regulated in our study, we studied
their immunolocalization in selected cases of four
main histological types (serous, endometrioid, clear
cell and mucinous) of ovarian cancer. Among stud-
ied tissue sections, immunoreactivity for PTEN (nu-
clear and cytoplasmic) was observed only in clear cell
(15% of cells) and mucinous types in about 5% (Fig-
ures 1A and 1B, respectively) whereas neither ex-
pression was observed in studied serous nor en-
dometrioid slides.
TP53 protein localization was nuclear and we could
observe strong reaction in 50–60% of endometrioid
(Figure 1C) and 80–90% of clear cell types (Figure 1D).
Very little or no reaction was observed in the serous
or mucinous types studied.
PIK3CA exhibited very strong immunohistochem-
ical reaction in all histological types studied and av-
erage staining was about 80% in serous, endometrio-
id and mucinous types (Figures 1E, 1F, 1G, respec-
tively), whereas we could observe that only 30% of
clear cell cancer cells showed, typical for all types,
cytoplasmic reaction (Figure 1H).
In the case of BECN1, we observed a weak cyto-
plasmic reaction in virtually all histological types
studied. In the cases of serous cancer sections, the
positive reaction was observed in only 5% of cells
(Figure 1I). Endometrioid cancer cells exhibited 10–
–12% positive reactions (Figure 1J). Despite the fact
that we did not observe a positive BECN1 reaction
in clear cell or mucinous cancer cells, in every histo-
logical type we could see characteristic vascular, spe-
cifically endothelial, positive reactions of this pro-
tein (see arrow in Figure 1I).
Discussion
A decrease in PTEN expression, which may lead to
loss of its function, is more frequent than can be ex-
plained by structural genomic changes alone, since
epigenetic phenomena, such as hypermethylation
of DNA, represent major restrictions to the tran-
scriptional process. PTEN expression can be lost
or greatly reduced in some tumors without any
mutation in the coding sequence of the gene in can-
cers of breast, prostate, non-small cell lung, as well
as ovarian cancer [15].
Schondorf et al. showed that expression of PTEN
is not altered in the progression of ovarian carcino-
ma, which suggests that in ovarian cancer PTEN does
not play a major role in disease progression [16]. An-
other study found that the level of PTEN mRNA ex-
pression was negatively correlated with clinicopatho-
logical staging of ovarian cancer, whereas it was posi-
tively correlated with histological differentiation. It has
also been shown that mRNA expression level of PTEN
gene in ovarian endometrioid cancer was significantly
lower than that in ovarian serous cancer [17]. In our
study, we were unable to show differences as to the ex-
pression of PTEN between those two histological types
of cancer. This was possibly due to an insufficient num-
ber of samples (eight endometrioid vs. 34 serous).
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Table 2. Detailed RQ and p values in three main study groups
Gene Ovarian cancer vs. Ovarian cancer Ovarian cancer Normal ovaries
normal ovaries (n = 53) vs. benign ovarian vs. benign
vs. benign vs. normal ovaries cysts (n = 29) ovarian cysts
ovarian cysts (n = 11)
NF1 0.0005* 0.294 (0.009–21.780) 0.294 (0.009–21.780) 0.614 (0.145–3.105)
vs. 0.614 (0.145–3.105)** vs. 3.772 (0.079–35.548) vs. 3.772 (0.079–35.548)
0.28*** 0.0003 0.04
RHEB 0.0006 0.923 (0.115–1027) 0.923 (0.115–1027) 0.583 (0.382–2.233)
vs. 0.583 (0.382–2.233)  vs. 5.134 (0.320–22.027) vs. 5.134 (0.320–22.027)
0.37 0.003 0.0007
mTOR 0.86 1.117 (0.179–100.386) 1.117 (0.179–100.386) 1.060 (0.629–2.853)
vs. 1.060 (0.629–2.853)  vs. 1.296 (0.195–7.809) vs. 1.296 (0.195–7.809)
0.8 0.62 0.81
PTEN 0.0003 0.164 (0.005–2549) 0.164 (0.005–2549) 8.181 (0.511–14.965)
vs. 8.18115 (0.511–14.965)  vs. 0.938 (0.062–7.380)  vs. 0.938 (0.062–7.380)
0.0019 0.017 0.003
TSC1 0.0005 0.532 (0.010–53.708) 0.532 (0.010–53.708) 1.153 (0.272–5.069)
vs. 1.153 (0.272–5.069)  vs. 5.182 (0.044–102.491)  vs. 5.182 (0.044–102.491)
0.11 0.0004 0.049
TSC2 0.03 0.537 (0.083–15.495) 0.537 (0.083–15.495) 0.858 (0.168–1.301)
vs 0.858 (0.168–1.301)  vs. 0.637 (0.146–2.615) vs. 0.637 (0.146–2.615)
0.06 0.026 0.57
KRAS 0.59 2.677 (0.381–623.826) 2.677 (0.381–623.826) 2.568 (1.444–5.431)
vs. 2.568 (1.444–5.431) vs. 3.653 (0.047–27.306) vs. 3.653 (0.047–27.306)
0.61 0.553 0.27
S6K1 0.0045 0.563 (0.019–250.998) 0.563 (0.019–250.998) 0.913 (0.335–3.641)
vs. 0.913 (0.335–3.641) vs. 3.967 (0.069–55.040) vs. 3.967 (0.069–55.040)
0.14 0.003 0.123
TP53 0.0003 0.707 (0.004–63.554) 0.707 (0.004–63.554) 1.256 (0.300–2.249)
vs. 1.256 (0.300–2.249)  vs. 1.357 (0.194–7.797)  vs. 1.357 (0.194–7.797)
0.03 0.0003 0.55
EIF4E 0.025 0.708 (0.071– 2633) 0.708 (0.071–2633) 0.772 (0.406–3.096)
vs. 0.772 (0.406–3.096)  vs. 5.422 (0.124–102.554)  vs. 5.422 (0.124–102.554)
0.68 0.014 0.04
LKB1 0.0001 0.508 (0.014–58.432) 0.508 (0.014–58.432) 0.736 (0.340–1.712)
vs. 0.736 (0.340–1.712)  vs. 1.348 (0.156–11.753) vs. 1.348 (0.156–11.753)
0.054 0.0001 0.07
PIK3CA < 0.0001 0.388 (0.038–63.337) 0.388 (0.038–63.337) 1.112 (0.141–3.256)
vs. 1.112 (0.141–3.256) vs. 0.998 (0.135–4.598) vs. 0.998 (0.135–4.598)
0.018 < 0.0001 0.98
BECN1 0.0014 0.599 (0.018–9.815) 0.599 (0.018–9.815) 1.077 (0.452–2.245)
vs. 1.077 (0.452–2.245)  vs. 1.197 (0.161–8.006) vs. 1.197 (0.161–8.006)
0.019 0.002 0.65
4EBP1 0.027 0.488 (0.062–97.736) 0.488 (0.062–97.736) 0.799 (0.330–5.507)
vs. 0.799 (0.330–5.507) vs. 1.574 (0.225–73.041)  vs. 1.574 (0.225–73.041)
0.14 0.015 0.49
AKT1 0.16 0.623 (0.025–244.898) 0.623 (0.025–244.898) 0.952 (0.412–5.140)
vs. 0.952 (0.412–5.140)  vs. 1.690 (0.193–99.022)  vs. 1.690 (0.193–99.022)
0.48 0.073 0.31
*Kruskal-Wallis test p-value (statistically significant value of less than 0.05) for comparison of three groups; **Relative quantity (RQ)
median values (minimum-maximum); ***Wilcoxon test p-value (statistically significant value of less than 0.05)
The decrease of autophagic capacity, related to
lower beclin-1 expression, has been recently shown
by immunohistochemical studies in epithelial ovari-
an cancer [18]. It has been found that BECN1 gene
levels were significantly higher in benign and bor-
derline ovarian tumors than in epithelial ovarian car-
cinoma. In another study, higher expressions of Be-
clin-1 protein were found in normal and benign ova-
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rian neoplasia tissues; the expressions were reduced
in the borderline lesion tissue and the lowest level
of expressions could be detected in the ovarian car-
cinoma tissue [19]. Although two of these studies
were published in Chinese, making it difficult to
describe methodology, we believe that the immun-
ostaining of Beclin-1 was prevalent in ovarian can-
cer specimens. In our study, we for the first time
confirmed that the median mRNA expression level
is lower in malignant compared to non-malignant
lesions of the ovaries, but the protein immunolocal-
ization is relatively scarce and weak.
Decreased levels of TP53 are not surprising since
inactivation of this gene appears to be an early step
Figure 1. Immunolocalization of PTEN, TP53, PIK3CA and BECN1 in
ovarian cancer. Photos show (magnification × 400) selected histological
sections of four main types i.e. serous, endometrioid, clear cell and mucinous.
On (A) and (B) nuclear and cytoplasmic expression of PTEN is presented in
clear cell and mucinous types of ovarian cancer respectively; (C) and (D) show
nuclear TP53 localization in endometrioid and clear cell types; PIK3CA
cytoplasmic reaction is shown in (E), (F), (G) and (H), respectively in: serous,
endometrioid, mucinous and clear cell types; (I) and (J) show weak cytoplasmic
BECN1 staining, respectively in serous and endometrioid cancer cells. Arrows
in (I) indicate strong BECN1 endothelial expression in serous ovarian cancer
A B C
D E F
G H I
J
in ovarian carcinogenesis and results most common-
ly from mutations, but also from export from nuclei
mutations in proteins regulating p53 activity, or
overexpression of MDM2 — an important negative
regulator of the TP53 [20]. On the other hand, some
interesting new studies have recently been pub-
lished on the role of PIK3CA in ovarian cancer,
which is frequently amplified, as well as its expres-
sion increased, at the RNA and protein level [21].
Approximately 40% of ovarian cancers show in-
creased copy numbers at 3q26, which contains
PIK3CA [21, 22]. Interestingly, the frequency of
PI3K-increases, and the RNA and protein levels
exceed those at the DNA level, suggesting that copy
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number-independent mechanisms also regulate
PI3K levels in ovarian cancer.
Although most studies have found increased am-
plification and mRNA expression, as cited above, it
was recently shown that the expression level of
PIK3CA does not differ between ovarian cancer and
healthy ovaries. In order to study the expression pro-
file of PI3K family in ovarian cancer, Zhang et al.
retrieved from their website [23] public expression
microarray data sets of human cancer and analyzed
data by a web-based microarray bioinformatic tool
called Oncomine [24]. After analysis of nine indepen-
dent microarray studies, including two ovarian can-
cer ones, they found that out of six significantly am-
plified PI3K genes, including PIK3CA, only PIK3R3
had a significantly upregulated mRNA expression
level in ovarian cancer compared to normal ovary in
both ovarian cancer studies [23]. No difference as to
the expression of PIK3CA was observed.
The differences as to the expression of PIK3CA
between other studies and our own may be partly due
to efficiency and adequacy in the collection of ovari-
an, malignant and non-malignant specimens (most of
the articles overlook this, or do not include detailed
data of RNA integrity analysis). In our study, after
RNA isolation and assessment of its integrity (by
means of so called RIN values — see methods) we
found that only in 53 of the initial 80 patients with
ovarian cancer were we able to obtain RNA that ful-
filled the acceptable criteria of RIN of at least 7 with
relatively clearly visible bands [25]. On the other hand,
the median RIN values of healthy ovaries (successful
collection in 11 of 19 patients), were about 8, and the
bands were in every case particularly clear (data not
shown). This in our view might point to lesser degra-
dation of this type of sample which could result in
higher absolute levels of expression of some of the
genes, possibly PIK3CA.
It is important to keep in mind that this may not
necessarily point to their potential role in this type of
tissue, since expression of three tumor suppressor
genes were, as could be expected, significantly lower.
This could suggest lesser degradation of correspond-
ing mRNAs. To be more certain of the most proper
tissue selection, laser captured microdissection is rec-
ommended which allows for targeted isolation of
RNA from clearly defined types of cells. This tech-
nique is currently being introduced in our laboratory
in order to assure the best sample selection.
In summary, our study shows that the low-density
pathway-focused qualitative gene array is a robust and
reproducible technique for quantifying expression of
multiple genes in such a heterogenous sample as the
ovary, including malignant and non-malignant lesions.
Our results also show that the downregulation of some
tumor suppressor genes and oncogenes may be asso-
ciated with the pathogenesis of ovarian cancer.
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